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Gliomas are the most common primary tumors of the central nervous system, around 70 % of the malignant brain
tumors are gliomas. In the NCCN Guideline Ver.1 2015, the assessment before systemic treatment, treatment
principles and prognosis factors of gliomas has significantly changed based on the researches up to date, we try
to analyze the reason and the effect of these changes. The most important change is the reintroduction of PCV
chemotherapy in systemic treatment, which narrows the gap of prognosis between WHO II and III gliomas. Other
changes including the assessment before systemic treatment, usage of RT and the promotion of evidence level
about the Tumor Treating Fields.
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The simple term of glioma consists of many different
types of tumors that arise from the neuroepithelial cell
in central nervous system, which vary greatly in their
histology, genetics, and clinical outcome. Basically, they
are divided into 4 grades by WHO 2007 Classificaton of
Tumors of the CNS. Despite of the Grade I gliomas which
are considered to be benign, Grade II-IV are all malignant.
Gliomas are the most common primary tumors of the
central nervous system, around 70 % of the malignant
brain tumors are gliomas, with a annually morbidity of 6/
100000 in the United States [1]. Besides grading, gliomas
are further classified into pathological subtypes of which
the most common include astrocytomas and oligodendro-
gliomas. Grade II astrocytomas and oligodendrogliomas
can progress to grade III anaplastic astrocytomas and
anaplastic oligodendrogliomas, respectively. Glioblastomas
(GBMs) are grade IV astrocytomas including mainly “pri-
mary GBMs” (95 %) and “secondary GBMs (5 %)” that
have progressed from clinically discernible grade II or III
astrocytomas [2].* Correspondence: neurochina@gmail.com
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System Cancers (Version1, 2015), the assessment before
systemic treatment, treatment principles and prognosis
factors of gliomas has significantly changed based on the
researches up to date, we try to analyze the reason and
the effect of these changes as below.Main text
1. The use of PCV treatment in gliomas.
As is mentioned in the Guidelines, chemotherapy is not
a traditional mainstay of upfront treatment for low-grade
gliomas. There are some data that support temozolomide
as adjuvant therapy, and it is included as a category 2B
recommendation in 2004 based on non-uniform panel
consensus.
Since the early 1990s, initial therapy for newly diagnosed
anaplastic oligodendrogliomas (AO) has become procar-
bazine, lomustine (CCNU), and vincristine (PCV), with or
without radiotherapy, in many centers [3]. But some of
the early trail shows that temozolomide shows a better
curative effect and do no good to overall survival [4–9].
Based on the final report of RTOC 9402 date back to
2013, situation has changed a little. Chemoradiotherapy,
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cannot emerge as the new standard of care, because temo-
zolomide is also effective for AO/AOA, and PCV is more
toxic [10]. The complete dramatical change turned out in
2014 when the long-term follow-up of the RTOG 9802
trial was published. Comparing 54 Gy of radiotherapy
(RT) with the same RT followed by adjuvant procarbazine,
CCNU, and vincristine (PCV) chemotherapy in high-risk
low-grade glioma shows a major increase in survival after
adjuvant PCV chemotherapy. Median overall survival in-
creased from 7.8 to 13.3 years, with a hazard ratio of
death of 0.59. This increase in survival was observed
despite the fact that 77 % of patients who progressed
after RT alone received salvage chemotherapy. With
this outcome, RT + PCV is now to be considered
standard of care for low-grade glioma requiring post-
surgical adjuvant treatment [11].
However, a number of regimens including PCV and
temozolomide are currently considered acceptable for
recurrence or progressive disease and confered survival
benefits in the long term. And it is for sure that patients
with low-grade oligodendrogliomas, especially those with
1p/19q deletions, may represent favorable candidates for
chemotherapy in light of good response rates, this has
never been prospectively determined, which makes PCV
treatment now has a category 1 recommendation in the
2015 version [12–20].
The classic PCV treatment including procarbazine,
lomustine (CCNU), and vincristine, and the usage is
below:
1st day: CCNU 110 mg/m2, Po.
8th day and 29th day: vincristine 1.4 mg/m2, iv.
8th day to 21st day: procarbazine 60 mg/m2per day, Po.
And the course of treatment is 6 weeks.
Cyclohexyl nitrosourea (CCNU), a cell cycle non-specific
medicine, is mostly sensitive to cells at the G1-S boundary
or early S phase, and has also inhibition to G2 phase. After
the product enters into the human body, its elements
breaks into two parts from ammonia formamide bond: one
part is the chlorine ethylamine, dissociaties chlorine to
form ethylene carbocation, gives play to the role of
alkylation, resulting in DNA strand breaks, RNA and
protein by alkylation, which is mainly related to the
anti-tumor effect; the other is carbamoyl portion, con-
verts to isocyanate, or ammonia and then gives play to
the role of ammonia formylation, reacting mainly with
proteins, especially with lysine acid terminal amino. It
is believed that this is mainly related to bone marrow
toxicity, ammonia formylation can also destroy some
enzyme protein, so DNA by alkylation damage is relatively
difficult to repair, which contribute to anti-cancer effect. Al-
though this product has the effects of alkylating agentt, buthas no cross-resistance with the general alkylating agent, so
also does with vincristine, procarbazine and Antimetabolite.
The function of vincristine is related to the concentra-
tion. At low concentrations, the product is combined
with the point of low affinity tubulin, and due to space
barrier and other factors, inhibit tubulin polymerization.
At high concentration, the product is combined with
high affinity points on tubulin, making the microtubules
gathered together and forming a kind of crystallization.
PCV program primarily make use of the characteristics
of its low concentration.
In vivo, procarbazine is oxidized by erythrocytes and
liver microsomal enzymesin to metabolite of azo procar-
bazine with antitumor effect, by the end of the N-methyl
transmethylation, the methyl is transferred to 7 of guan-
ine and 1 of adenine and alkylated. Furthemore, the me-
thyl can also be transferred to the tRNA, which inhibiting
not only synthesis of DNA and RNA, but also protein
synthesis.
The recommendation to the PCV treatment has chan-
ged the guideline to a great extent. First of all, the progno-
sis importance and the guiding function of the biomarkers
in gliomas would significantly change due to the treatment
of PCV, considering it has a totally different theory com-
paring to the temozolomide. Meanwhile, the combination
of RT and PCV chemotherapy has a more stable progno-
sis, regardless of the preoperative state of the patients,
which lead to the other change in the Guideline Ver.1
2015. Moreover, PCV can narrow the gap between the
prognosis of WHO II and WHOIII gliomas, which means
a better curative effect than temozolomide. And the most
important is that because of the treatment of PCV and RT
is not so limited comparing to the temozolomide, max-
imal safe resection or subtotal resection would become
the most important prognosis index. Taking these into
consideration, the treatment of PCV maybe the most im-
portant change in the Guideline Ver.1 2015.
2. The change to the classification of low risk and high
risk patients in low-grade gliomas and glioblastoma
Beside the change to the systemic therapy, the clas-
sification of preoperative state in patients has changed.
The following are used to be considered as low-risk
features in the past version of guideline: age < 40 years,
Karnofsky Performance Status (KPS) ≥ 70, minor or no
neurologic deficit, ologodendroglioma or mixed oli-
goastrocytoma, tumor dimension <6 cm, 1p/19q co-
deleted, and IDH 1 or 2 mutated. Otherwise would be
high-risk. But now, the classification has been simpli-
fied to only considering resection range and the age.
Considering the background that the enormous devel-
opment of the Precision Medicine, this simplification
may be very confusing.
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is related to a series of trails, which shows that the
systemic therapy, especially PCV + RT, would benefit pa-
tients in the long term [21]. By this means, patients who
are treated with gross total resection (GTR) would bene-
fit much more than those who are not. Such change can
also be found in the treatment and prognosis to the glio-
blastomas. As is mentioned in the Guideline, age, rather
than KPS is a key option in the decision tree branch
points. The complex assessment before systemic treat-
ment including biomarkers and neurologic deficit is
abandoned, which makes it easier to evaluate the prog-
nosis of patients and to choose the therapeutic regimen.
This change means operation has turn into the most
important factor in prognosis, whether the preoperative
state of the patients is good or not. By this means, sur-
gery may become the most important treatment and
GTR can never be emphasized too much.
However, the changes in classification do not mean
the recession of molecular pathology. In fact, in the trails
ROTC 9802, studies on molecular correlates associated
with response are still lacking [11]. That means further
researches should be run to reevaluate the prognosis
function of IDH1, TRET, EGFR, 1p/19q and p53 under
the treatment of PCV + RT. In a similar way, KPS and
preoperative state are also should be re-evaluated. It is
certain that it would be an enormous variation to the
prognostic values of most of the molecular biomarkers.
3. Other changes in Guideline
RT alone after operation is no longer an option of treat-
ment. A series of trails show that patients of low-grade and
high-grade gliomas would benefit from RT+ chemotherapy
[22–24], which means chemotherapy raises its importance.
Still, thanks to the use of PCV treatment.
Meanwhile, the dose of RT for high-grade gliomas has
changed, the recommended dose used to be 60Gy in 1.8
to 2.0Gy fractions, now it is 2.0Gy fractions only. Which
means a more focused RT program is recommended.
Moreover, the evidence level of alternating electric
field therapy has been lifted from category 3 to category
2B. It is based on the results of a clinical trial that ran-
domized 237 patients to Tumor Treating Fields (TTF)
or chemotherapy. The results show the similar survival
in the two arms, and TTF therapy was associated with
lower toxicity and improved quality of life [25].
4. Predictions for the development of the Guideline
The GTR will own a higher position in the treatment of
gliomas, which means, with the development of systemic
treatment, neurosurgery operation will getting increasingly-
important than before. And the assessment before systemictreatment will focus on resection and age, KPS will be less
valued. Considering the development of systemic therapy,
this trend is definitely continue in the next version of
Guideline and will affect clinical strategy to a great extent.
Due to the reintroduction of PCV, most of the bio-
markers prognosis function would change a lot, on ac-
count of they are used to be mainly connected with RT
and Temozolmide. Though they are less linked with the
assessment before systemic treatment, biomarkers which
are the basement of the Precision Medicine, will play an
increasingly - important role in the guideline to conduct
the prognosis and treatment.
Conclusions
NCCN Guidelines of Central Nervous System Cancers
about low-grade gliomas and glioblastoma Ver.1 2015
shows a trend of simplification of the assessment before
systemic treatment and emphasize the importance of
GTR and systemic treatment including PCV and RT. In
a word, less is more.
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